Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 11/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.43 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.42 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17515545 | 0.98 | RBP4 (0.48) | RBP4GFERHCRTR1HCRTR2PLA2G1B | |
| SCHEMBL16124088 | 0.90 | RBP4 (0.47) | RBP4GFERHCRTR1HCRTR2 | |
| SCHEMBL17518218 | 0.87 | RBP4 (0.52) | RBP4HCRTR1HCRTR2 | |
| SCHEMBL17518219 | 0.87 | RBP4 (0.52) | RBP4HCRTR1HCRTR2 | |
| SCHEMBL16124082 | 0.86 | RBP4 (0.48) | RBP4HCRTR1HCRTR2 | |
| SCHEMBL16124084 | 0.86 | RBP4 (0.52) | RBP4HCRTR1HCRTR2 | |
| SCHEMBL16124085 | 0.85 | RBP4 (0.50) | RBP4HCRTR1HCRTR2 | |
| SCHEMBL17518155 | 0.85 | RBP4 (0.53) | RBP4MAPK1 | |
| SCHEMBL17518284 | 0.85 | RBP4 (0.61) | RBP4 | |
| SCHEMBL16124089 | 0.85 | RBP4 (0.53) | RBP4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230241049-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2023-08-03 | — | — | US | disclosed |
| US-9944644-B2 | Octahydropyrrolopyrroles their preparation and use | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160046632-A1 | OCTAHYDROPYRROLOPYRROLES THEIR PREPARATION AND USE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046632-A1 | OCTAHYDROPYRROLOPYRROLES THEIR PREPARATION AND USE | QDPR, DPYD, DHPS | RBP4 4178/4885GFER 2181/4885HCRTR1 995/4885 |
| US-20230241049-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | RBP4, RBP1, FABP1 | RBP4 1/4885GFER 2058/4885HCRTR1 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.